Naimish Patel
Fortune : 1 M $ au 31/05/2026
Fortune : 1 M $ au 31/05/2026
Naimish Patel is currently Chief Medical Officer at CRISPR Therapeutics AG since 2024.
Formerly, Dr. Patel was Global Head-Dupilumab Program at Sanofi.
Education includes a doctorate from McGill University and an undergraduate degree from Massachusetts Institute of Technology.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CRISPR THERAPEUTICS AG 0,02 % | 29/05/2026 | 19 357 ( 0,02 % ) | 1 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| CRISPR THERAPEUTICS AG | Directeur Technique/Scientifique/R&D | 28/05/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
| SANOFI | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Sanofi
Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
CRISPR Therapeutics AG
CRISPR Therapeutics AG BiotechnologyHealth Technology Develops gene-based medicines | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national